Lenz Therapeutics Shares Plunge After Weak Q4 Results

Shares of Lenz Therapeutics experienced a sharp decline of 11.2% by 9:50 a.m. ET on Tuesday, following the release of disappointing fourth-quarter earnings that fell short of expectations. Prior to the earnings announcement, Wall Street analysts had anticipated that Lenz would report a loss of $0.90

Shares of Lenz Therapeutics experienced a sharp decline of 11.2% by 9:50 a.m. ET on Tuesday, following the release of disappointing fourth-quarter earnings that fell short of expectations.

Prior to the earnings announcement, Wall Street analysts had anticipated that Lenz would report a loss of $0.90 per share alongside quarterly revenue of $3.1 million. However, the company disclosed a steeper loss of $1.16 per share, accompanied by revenue of just $1.6 million, which triggered the immediate sell-off in its stock price.

Introducing VIZZ from Lenz

Lenz operates as a pharmaceutical firm dedicated to innovating treatments for presbyopia, a common condition characterized by blurred near vision that typically emerges around the age of 50 in the majority of adults, serving as a viable alternative to traditional reading glasses. The flagship product, VIZZ eye drops, comes in convenient single-dose vials and offers temporary enhancement of near vision for as long as 10 hours with just one daily application. This improvement occurs through the contraction of eye muscles, enabling sharper focus on close-up objects.

Lenz initiated commercial sales of VIZZ in October 2025, marking the fourth quarter as its inaugural launch period. Company executives reported steady progress, projecting a total of 45,000 prescriptions issued by the conclusion of the first quarter of 2026, involving contributions from more than 10,000 eye care professionals. Regrettably, the adoption rate during the Q4 launch quarter fell below the optimistic projections set by financial markets.

A primary factor contributing to the earnings miss appears to be the dramatic surge in the company's selling, general, and administrative expenses, or SG&A, which approximately quadrupled amid the intensive efforts to drive initial product sales and market penetration.

What's Next for Lenz?

Looking ahead, a key question remains whether these elevated SG&A costs will moderate throughout 2026, potentially paving the way for Lenz to achieve profitability. Disappointingly, the management team provided limited forward-looking guidance during the earnings call, leaving investors with scant details on anticipated performance for the upcoming year. In fact, their reference to "over 45,000 paid prescriptions from launch through Q1 2026" deliberately avoids revealing specific growth trends in prescription volumes between the Q4 2025 launch phase and the subsequent Q1 2026 period.

This lack of transparency regarding the trajectory of product acceptance and demand growth has left analysts and shareholders uncertain about the company's momentum. Market participants generally react negatively to such ambiguity, which explains the ongoing pressure on Lenz Therapeutics' stock price as investors reassess their positions in light of the unclear outlook.